- Home
- TD vs SNY Comparison
TD vs SNY Comparison
Compare TD & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TD
- SNY
- Stock Information
- Founded
- TD 1855
- SNY 1994
- Country
- TD Canada
- SNY France
- Employees
- TD N/A
- SNY N/A
- Industry
- TD
- SNY Biotechnology: Pharmaceutical Preparations
- Sector
- TD
- SNY Health Care
- Exchange
- TD Nasdaq
- SNY Nasdaq
- Market Cap
- TD 126.6B
- SNY 116.5B
- IPO Year
- TD N/A
- SNY N/A
- Fundamental
- Price
- TD $74.51
- SNY $49.04
- Analyst Decision
- TD Buy
- SNY Buy
- Analyst Count
- TD 2
- SNY 2
- Target Price
- TD $91.50
- SNY $65.00
- AVG Volume (30 Days)
- TD 1.8M
- SNY 2.6M
- Earning Date
- TD 08-28-2025
- SNY 07-31-2025
- Dividend Yield
- TD 4.00%
- SNY 3.26%
- EPS Growth
- TD 63.11
- SNY 118.56
- EPS
- TD 6.97
- SNY 8.65
- Revenue
- TD $45,024,677,580.00
- SNY $53,714,621,258.00
- Revenue This Year
- TD $10.95
- SNY $2.85
- Revenue Next Year
- TD $3.82
- SNY $6.65
- P/E Ratio
- TD $10.69
- SNY $5.67
- Revenue Growth
- TD 20.69
- SNY 15.65
- 52 Week Low
- TD $51.25
- SNY $44.73
- 52 Week High
- TD $75.58
- SNY $60.12
- Technical
- Relative Strength Index (RSI)
- TD 59.48
- SNY 53.96
- Support Level
- TD $72.72
- SNY $46.14
- Resistance Level
- TD $73.80
- SNY $47.54
- Average True Range (ATR)
- TD 0.78
- SNY 0.82
- MACD
- TD -0.03
- SNY 0.14
- Stochastic Oscillator
- TD 90.71
- SNY 82.41
About TD Toronto Dominion Bank (The)
Toronto-Dominion is one of Canada's two largest banks with over CAD 2 trillion in assets. TD Bank operates four business segments: Canadian personal and commercial banking, US retail banking, wealth management and insurance, and wholesale banking. The bank derives more than 55% of its revenue from Canada and has dominant market share in nearly all banking products and services. TD has around 40% of its revenue from its US operations. Its US footprint spans from Maine to Florida, with a strong presence in the Northeast.
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in vaccines, immunology, oncology, cardiovascular disease, diabetes, and over-the-counter treatments. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing about 30% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.